Bright Minds Biosciences, Inc. (DRUG)
20.75
+1.79
(+9.44%)
USD |
NASDAQ |
Nov 05, 16:00
20.76
+0.01
(+0.05%)
After-Hours: 20:00
Bright Minds Biosciences Enterprise Value : -29.90M for Nov. 4, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2026 | -29.90M |
| November 03, 2026 | -4.354M |
| November 02, 2026 | 41.51M |
| October 30, 2026 | 325.40M |
| October 29, 2026 | 342.27M |
| October 28, 2026 | 328.76M |
| October 27, 2026 | 315.93M |
| October 26, 2026 | 287.03M |
| October 23, 2026 | 300.74M |
| October 22, 2026 | 302.81M |
| October 21, 2026 | 280.62M |
| October 20, 2026 | 327.57M |
| October 19, 2026 | 313.96M |
| October 16, 2026 | 289.10M |
| October 15, 2026 | 317.81M |
| October 14, 2026 | 283.28M |
| October 13, 2026 | 289.69M |
| October 12, 2026 | 315.83M |
| October 09, 2026 | 316.23M |
| October 08, 2026 | 296.01M |
| October 07, 2026 | 296.01M |
| October 06, 2026 | 259.02M |
| October 05, 2026 | 274.21M |
| October 02, 2026 | 283.09M |
| October 01, 2026 | 268.49M |
| Date | Value |
|---|---|
| September 30, 2026 | 274.50M |
| September 29, 2026 | 273.71M |
| September 28, 2026 | 292.65M |
| September 25, 2026 | 294.04M |
| September 24, 2026 | 310.90M |
| September 23, 2026 | 354.40M |
| September 22, 2026 | 381.53M |
| September 21, 2026 | 369.59M |
| September 18, 2026 | 384.59M |
| September 17, 2026 | 390.21M |
| September 16, 2026 | 366.14M |
| September 15, 2026 | 377.09M |
| September 14, 2026 | 408.26M |
| September 11, 2026 | 406.29M |
| September 10, 2026 | 424.24M |
| September 09, 2026 | 424.83M |
| September 08, 2026 | 443.08M |
| September 04, 2026 | 425.82M |
| September 03, 2026 | 454.03M |
| September 02, 2026 | 484.61M |
| September 01, 2026 | 481.85M |
| August 31, 2026 | 490.63M |
| August 28, 2026 | 501.28M |
| August 27, 2026 | 518.30M |
| August 26, 2026 | 538.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 299.67B |
| Lineage Cell Therapeutics, Inc. | 210.85M |
| Recursion Pharmaceuticals, Inc. | 1.695B |
| Agenus, Inc. | 561.69M |
| Anika Therapeutics, Inc. | 259.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.732M |
| Total Expenses (Quarterly) | 1.732M |
| EPS Diluted (Quarterly) | -0.1762 |
| Earnings Yield | -10.04% |
| Normalized Earnings Yield | -10.04 |